Medtechs made it out of Q2 with minimal impact from delta. That could change in Q3.

Medtechs made it out of Q2 with minimal impact from delta. That could change in Q3.

Source: 
Medtech Dive
snippet: 

Procedure-dependent companies reported little to no impact from the variant in the second quarter. But rising COVID-19 cases and elective shutdowns pose a risk in the second half of the year.